Acquisition by Richard Heyman of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for Syndax Pharmaceuticals | Syndax Pharmaceuticals Hype Analysis

Acquisition of 25600 stock option (right to buy) at 7.9 of Oric Pharmaceuticals by Richard Heyman on 12th of June 2024. This event was filed by Oric Pharmaceuticals with SEC on 2024-06-12. Statement of changes in beneficial ownership - SEC Form 4

We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.